If you are prescribed Qsymia as part of your medical weight loss program, it is beneficial to work closely with your doctor to make sure that you are incorporating the appropriate lifestyle changes along with your new medication.
Qsymia can be a beneficial aid in weight loss, but you want to ensure that your weight loss provides lasting results. The way to do this is through dedication to long-term lifestyle changes for your overall health and wellness. While there is a possibility of certain side effects while on Qsymia, you can reduce your chances of developing any of these by making sure you are talking the proper dosage and working closely with your weight loss doctor.
During medical weight loss, you may need additional help to lose weight effectively. This is where Qsymia may come in. Patients with a history of depression may be at increased risk.
For clinically significant or persistent symptoms consider dose reduction or withdrawal of Qsymia. Qsymia can cause cognitive dysfunction e. Since Qsymia has the potential to impair cognitive function, patients should be cautioned about operating hazardous machinery, including automobiles. Hyperchloremic, non-anion gap, metabolic acidosis has been reported in patients treated with Qsymia.
Measurement of electrolytes including serum bicarbonate prior to starting Qsymia and during Qsymia treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing Qsymia. Qsymia can cause an increase in serum creatinine that reflects a decrease in renal function glomerular filtration rate. In phase 3 trials, peak increases in serum creatinine were observed after 4 to 8 weeks of treatment. On average, serum creatinine gradually declined but remained elevated over baseline creatinine values.
The changes in serum creatinine and measured GFR with short-term Qsymia treatment appear reversible with treatment discontinuation, but the effect of chronic treatment on renal function is not known. Therefore, measurement of serum creatinine prior to starting Qsymia and during Qsymia treatment is recommended.
If persistent elevations in creatinine occur while taking Qsymia, reduce the dose or discontinue Qsymia. Qsymia has not been studied in combination with insulin. Measurement of blood glucose levels prior to starting Qsymia and during Qsymia treatment is recommended in patients with type 2 diabetes. A reduction in the dose of antidiabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. In hypertensive patients being treated with antihypertensive medications, weight loss may increase the risk of hypotension.
Measurement of blood pressure prior to starting Qsymia and during Qsymia treatment is recommended in patients being treated for hypertension. If a patient develops symptoms associated with low blood pressure after starting Qsymia, appropriate changes should be made to the antihypertensive drug regimen. The concomitant use of alcohol or central nervous system CNS depressant drugs e. Therefore, avoid concomitant use of alcohol with Qsymia. In situations where immediate termination of Qsymia is medically required, appropriate monitoring is recommended.
Adjust dose of Qsymia for patients with moderate or severe renal impairment. Qsymia has not been studied in patients with end-stage renal disease on dialysis. Avoid use of Qsymia in this patient population. Adjust dose of Qsymia for patients with moderate hepatic impairment.
Speak with your physician about this, because he or she might have to adjust your diabetes medications. What have clinical trials shown? Last year, a study funded by Vivus, Inc. In a placebo-controlled clinical trial, those who took Qsymia lost an average of 8. Seventy percent of those taking Qsymia lost at least 5 percent of their body weight compared to only 20 percent of those on the placebo.
Qsymia was initially denied FDA approval in because of potential side effects, including heart palpitations and birth defects if taken by pregnant women such as cleft lip or palate. After the current approval process, Vivus agreed to conduct further testing to show that Qsymia does not have dangerous cardiovascular side effects.
Clinical trials have already shown that Qsymia can lower blood pressure, reducing the risk of heart attack and stroke. When will Qsymia be available for use? The overall consensus is that the best way to keep off unwanted weight is through a healthy lifestyle, including proper nutrition and exercise. Qsymia can act as the jumpstart that many people need to get on the road to weight loss. As always, speak with your doctor before beginning any diet or exercise regimen.
FDA approves new weight-loss drug Qsymia Drs.
0コメント